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Kinins are a family of vasoactive peptides implicated in 
cardiovascular regulation, inflammation, and nociception. 
Most of their effects are mediated by the activation of two 
G protein-coupled receptors, B1 and B2. The B2 receptor 
binds bradykinin with high affinity in rodents. In humans, 
the preferred agonist is kallidin or lys-bradykinin. The B1 
receptor favors carboxy-metabolites, des-Arg9-bradykinin 
in rodents and des-Arg10-kallidin in humans. B2 receptors 
are constitutive entities while B1 receptors are inducible 
molecules that may be upregulated under special 
circumstances [1]. B2 receptors are putative “good guys” 
that modulate blood coagulation by exerting 
antithrombotic and profibrinolytic actions. They signal the 
release of nitric oxide and prostacyclin, thereby inhibiting 
vascular smooth muscle cell growth and neointimal 
formation, actions which could slow down the 
development of atherosclerosis and diabetes-mediated 
target organ damage. B1 receptors are induced by 
proinflammatory elements, including endotoxin, 
lipopolysaccharides, cytokines, or B1 receptor agonists. 
Innate immunity and pain are obviously important defense 
mechanisms. However, the inducible B1 receptor has 
become a desirable drug target when these responses 
should be held in check. The upregulation of the B1 
receptor is a rather novel feature of this inflammatory 
pathway. The B1 receptor gene promoter is outfitted with 
a nuclear factor-kappaB binding site that plays a 
regulatory role, particularly when the receptor is 
upregulated in response to interleukin-1 beta, tumor 
necrosis factor-alpha, and lipopolysaccharide (LPS). A 
schema suggested by Calixto et al. [1] is shown in outline 
form (Fig. 1). 
Merino et al. [2] report in this issue that overexpression of 
the B1 receptor on the endothelial cells of transgenic rats 
increase the susceptibility to endotoxic (LPS-mediated) 
shock. Endothelium-specific expression was achieved 
using the mouse Tie2 promoter/enhancer. The entire 12.7 
kb transgene fragment was then introduced into the 
pronuclei of fertilized zygotes from Sprague Dawley rats. 
Ribonuclease A protection assay confirmed generalized 
endothelial expression of the transgene in multiple 
organs. This receptor was expressed constitutively, since 
des-Arg9-bradykinin elicited dose-dependent aortic 
relaxation in transgenic rats, an effect that was abolished 
by endothelial removal. The effect was influenced by 
tetraethylammonium and oubain suggesting participation 
of potassium channels and sodium–potassium ATPase. 
Cytochrome P450 enzymes and prostaglandins were not 
involved. Des-Arg9-bradykinin lowered blood pressure in 
the otherwise normotensive transgenic rats, an effect that 
was nitric oxide-dependent, since an NO synthase 
inhibitor diminished the effect. Next, the authors 
performed vascular permeability studies with Evans Blue 
administered via the tail vein. Des-Arg9-bradykinin 
resulted in dye extravasation. Finally, the stage was set 
for the LPS experiments. Transgenic and control rats 
were injected with LPS. Transgenic rats became more 
hypotensive and half the animals died, compared to no 
deaths among the controls. 
The results are not surprising. A mouse generalized 
transgenic B1 receptor model had already shown that 
increased B1 receptor expression increases the 
propensity to LPS-mediated shock [3]. The fact that the 
B1 receptor now no longer had to be first upregulated and 
that it was expressed in great abundance also favored a 
positive result in this study. The authors claim that 
endothelial-specific targeting is a novelty in their study. 
Can anything else be learned from this model? The model 
could be used in drug development. Peptidergic B1 
receptor antagonists have been around since about 1977. 
They are subject to proteolytic degradation and are 
potentially antigenic. However, nonpeptidergic B1 
receptor antagonists are undergoing study [4]. One 
potential example is the novel benzamide B1 receptor 
antagonist 7-chloro-2-[3-(9-pyridin-4-yl-3,9-diaza-
spiro[5.5] undecanecarbonyl) phenyl]-2,3-di hydro-iso-
indol-1-one (ELN441958) [5]. Species specificity could be 
a problem, since Merino et al. relied on a mouse B1 and 
not a human B1 construct [2]. ELN441958 is 120-fold 
more potent for the primate than for the rodent B1 
receptor. Furthermore, septic shock is a complicated 
entity. B1 antagonists might have a brighter future in the 
management of neuropathic pain. 
An alternative use for the model might be in further 
studies of the renin–angiotensin system. The 
aspartylprotease renin cleaves angiotensinogen to 
angiotensin (Ang) I, which is converted to the active 
agonist Ang II by the angiotensin converting enzyme 
(ACE). ACE is also known as kininase II and was 
originally described as degrading bradykinin. ACE 
inhibitors are commonly used in cardiovascular medicine 
and there effects have been in part attributed to their 
actions that hinder the degradation of bradykinin. The 
relationship between the kinin system and the renin–
angiotensin system by no means stops there. Recently, 
Ceravolo et al. [6] observed that infused Ang II induces B1 
receptor expression in the aortas of rats. Furthermore, 
Ignjatovic et al. [7] have observed that ACE inhibitors can 
activate B1 receptors. This latter observation is 
particularly interesting since the activation occurred in the 
absence of ACE and absence of des-Arg-kinins, namely, 
the agonists. Ignjatovic et al. found that the B1 receptor 
contains a Zn-binding pentameric consensus sequence 
that is absent in B2 receptors. The model developed by 
Merino et al. [2] should go into shock when treated with an 
ACE inhibitor but not when given an Ang II AT1 receptor 
blocker. ACE also cross talks with the B2 kinin receptor 
[8]. Benzing et al. [9] showed that ACE inhibitors enhance 
the vascular response to bradykinin by influencing the 
distribution of B2 receptors within the plasma membrane. 
However, that finding is not directly relevant to this 
discussion. 
Another interaction that could be studied in this LPS-
induced shock model is NO (shown in this study), ACE 
expression, and ACE2 expression. ACE2 is another 
matrix metalloproteinase that can convert Ang II to Ang(1–
7), a heptapeptide with effects totally different than Ang II, 
namely, blood pressure lowering, vasodilatory, and 
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antiproliferative. ACE2 also serves as a Corona virus 
receptor on pulmonary epithelium. Gupta et al. [10] 
recently observed that activated protein C ameliorates 
LPS-induced renal injury by downregulating inflammatory 
NO synthase and ACE expression. Instead, activated 
protein C upregulated ACE2 expression, which should 
increase Ang(1–7) and protect from acute respiratory 
distress syndrome. With these suggestions, Merino et al. 
[2] should have something for their transgenic rats to do. 
In any event, armed with these suggestions, they can now 
counter the deadly question: “Why was this study done?” 
Respectfully, 
Friedrich C. Luft 
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Fig.1: Possible mechanisms of B1 receptor upregulation are shown. LPS 
stimulates Toll-like receptors (TLR). Cytokines, growth factors, and even B1 
agonists can upregulate this otherwise not constitutive receptor. A series of kinases 
perform intermediate signaling. The transcription factors involved include 
CCAAT/enhancer binding protein (CREB), activator protein-1 (AP-1), and nuclear 
factor-kappaB (NF-κB). Adapted from [1]. 
 
